» Articles » PMID: 15207265

Genetic and Phenotypic Characterization of Tumor Cells Derived from Malignant Peripheral Nerve Sheath Tumors of Neurofibromatosis Type 1 Patients

Overview
Journal Neurobiol Dis
Specialty Neurology
Date 2004 Jun 23
PMID 15207265
Citations 42
Authors
Affiliations
Soon will be listed here.
Abstract

Neurofibromatosis type 1 (NF1) patients have an 8-13% lifetime risk of developing malignant peripheral nerve sheath tumors (MPNST) which have a very poor prognosis. In this study, cells from eight MPNSTs (six primary and two recurrences) of six clinically and genetically well-characterized NF1 patients were taken into culture. Tracing of loss of heterozygosity (LOH) of the NF1, p53, and p16 gene regions or of abnormal karyotypes enabled identification of tumor cells from five MPNSTs. In two other MPNST-derived cell cultures, LOH of the relevant regions in the original tumors could not be detected, indicating that the obtained cells were nonneoplastic cells. Cells from most MPNSTs grew only under standard culture conditions but not under conditions optimized for Schwann cells. These cells were S100-negative and did not exhibit spindle shape which is a characteristic of Schwann cells. Drastically increased proliferation rates were found for most of the MPNST cells in comparison to Schwann cells derived from benign neurofibromas. Our study demonstrates that genetic analysis is effective and essential for verification of MPNST tumor cells in culture. These verified MPNST cells are valuable for further investigations of the biology and pathogenesis of this malignancy as well as for in vitro pharmacologic studies essential for the development of new therapies.

Citing Articles

Triple Combination of MEK, BET, and CDK Inhibitors Significantly Reduces Human Malignant Peripheral Nerve Sheath Tumors in Mouse Models.

Ortega-Bertran S, Fernandez-Rodriguez J, Magallon-Lorenz M, Zhang X, Creus-Bachiller E, Diazgranados A Clin Cancer Res. 2025; 31(5):907-920.

PMID: 39786423 PMC: 11873804. DOI: 10.1158/1078-0432.CCR-24-2807.


Two Different Pathogenic Variants in a Family With Neurofibromatosis Type 1.

Hartung T, Kluwe L, Friedrich R, Farschtschi S Cancer Genomics Proteomics. 2024; 22(1):41-45.

PMID: 39730180 PMC: 11696324. DOI: 10.21873/cgp.20485.


NF2 with NF1 Features a Unique Overlap.

Vishnoi K, Yadav S, Garg D, Nagpure P, Gupta P Indian J Otolaryngol Head Neck Surg. 2024; 76(6):5930-5934.

PMID: 39559002 PMC: 11569372. DOI: 10.1007/s12070-024-04994-0.


Silver Nanoparticles Selectively Treat Neurofibromatosis Type 1-Associated Plexiform Neurofibroma Cells at Doses That Do Not Affect Patient-Matched Schwann Cells.

Attiah B, Alewine G, Easter M, Coover R, Fahrenholtz C Pharmaceutics. 2024; 16(3).

PMID: 38543265 PMC: 10975375. DOI: 10.3390/pharmaceutics16030371.


Multiplatform molecular profiling uncovers two subgroups of malignant peripheral nerve sheath tumors with distinct therapeutic vulnerabilities.

Suppiah S, Mansouri S, Mamatjan Y, Liu J, Bhunia M, Patil V Nat Commun. 2023; 14(1):2696.

PMID: 37164978 PMC: 10172395. DOI: 10.1038/s41467-023-38432-6.